Enovis (ENOV) Stock Forecast & Price Target

Compare

301 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

ENOV Analyst Ratings

Strong Buy

9 Buy

0 Hold

0 Sell

Based on 9 analysts giving stock ratings to

Enovis

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

ENOV Stock 12 Month Forecast

Average Price Target

$45.25

▲(110.86% Upside)

Based on 9 Wall Street analysts offering 12 month price targets for Enovis in the last 3 months. The average price target is $45.25 with a high forecast of $50.00 and a low forecast of $40.00. The average price target represents a 110.86% change from the last price of $21.46.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"24":"$24","51":"$51","30.75":"$30.8","37.5":"$37.5","44.25":"$44.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":50,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$50.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":45.25,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$45.25</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":40,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$40.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[24,30.75,37.5,44.25,51],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Apr<br/>2025","6":"Jul<br/>2025","9":"Oct<br/>2025","12":"Jan<br/>2026","25":"Jan<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,26.64,28.436923076923076,30.233846153846155,32.03076923076923,33.82769230769231,35.62461538461538,37.42153846153846,39.21846153846154,41.01538461538462,42.81230769230769,44.60923076923077,46.40615384615384,48.20307692307692,{"y":50,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,26.64,28.071538461538463,29.503076923076925,30.934615384615384,32.36615384615385,33.79769230769231,35.22923076923077,36.66076923076923,38.09230769230769,39.52384615384615,40.95538461538462,42.386923076923075,43.818461538461534,{"y":45.25,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,26.64,27.66769230769231,28.695384615384615,29.723076923076924,30.75076923076923,31.77846153846154,32.80615384615385,33.83384615384615,34.86153846153846,35.88923076923077,36.91692307692308,37.94461538461539,38.972307692307695,{"y":40,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":43.88,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":46.98,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":38.65,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":37.18,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34.6,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.65,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.02,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.74,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":30.84,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 27, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":30.46,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 44, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.24,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 53, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.36,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 44, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.64,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 36, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$50.00

Average Price Target$45.25

Lowest Price Target$40.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Ryan Zimmerman

BTIG

$41

Buy

91.05%

Upside

Reiterated

01/22/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Enovis (NYSE: ENOV), Guardian Pharmacy Services, Inc. Class A (NYSE: GRDN) and Biogen (NASDAQ: BIIB)

Brandon Vazquez

William Blair

Buy

―

Reiterated

01/13/26

Enovis: Discounted Valuation and Improving Profitability Support Buy Rating Despite Near-Term Growth Headwinds

Vijay Kumar

Evercore ISI

$40

Buy

86.39%

Upside

Reiterated

01/12/26

Enovis free cash flow set to improve in FY26, says Evercore ISIEnovis free cash flow set to improve in FY26, says Evercore ISI

Danielle Antalffy

UBS

$57→$50

Buy

132.99%

Upside

Reiterated

01/05/26

Analysts' Opinions Are Mixed on These Healthcare Stocks: Zoetis (NYSE: ZTS), Enovis (NYSE: ENOV) and Icon (NASDAQ: ICLR)

Caitlin Cronin

Canaccord Genuity

$58→$50

Buy

132.99%

Upside

Reiterated

12/17/25

Enovis (ENOV) Gets a Buy from Canaccord Genuity

Keith Hinton

Freedom Capital Markets

$45

Buy

109.69%

Upside

Initiated

12/16/25

Enovis (ENOV) Initiated with a Buy at Freedom Capital Markets

Jeff Johnson

Robert W. Baird

$50→$45

Buy

109.69%

Upside

Reiterated

11/07/25

Enovis price target lowered to $45 from $50 at BairdEnovis price target lowered to $45 from $50 at Baird

Vik Chopra

Wells Fargo

$41→$42

Buy

95.71%

Upside

Reiterated

11/07/25

Michael Matson

Needham

$49

Buy

128.33%

Upside

Reiterated

11/06/25

Enovis: Strong Financial Performance and Growth Potential Justify Buy Rating

Robbie Marcus

J.P. Morgan

$33

Hold

53.77%

Upside

Reiterated

08/08/25

Analysts' Top Healthcare Picks: DENTSPLY SIRONA (XRAY), Replimune Group (REPL)

Jason Wittes

Roth MKM

$75

Buy

249.49%

Upside

Reiterated

08/08/25

Enovis (ENOV) Gets a Buy from Roth MKM

Young Li

Jefferies

$60

Buy

179.59%

Upside

Reiterated

05/30/25

Optimistic Buy Rating for Enovis: Strong Growth, Margin Expansion, and Attractive Valuation

David Turkaly

Citizens JMP

$62→$55

Buy

156.29%

Upside

Reiterated

05/09/25

Enovis price target lowered to $55 from $62 at Citizens JMPEnovis price target lowered to $55 from $62 at Citizens JMP

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Ryan Zimmerman

BTIG

$41

Buy

91.05%

Upside

Reiterated

01/22/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Enovis (NYSE: ENOV), Guardian Pharmacy Services, Inc. Class A (NYSE: GRDN) and Biogen (NASDAQ: BIIB)

Brandon Vazquez

William Blair

Buy

―

Reiterated

01/13/26

Enovis: Discounted Valuation and Improving Profitability Support Buy Rating Despite Near-Term Growth Headwinds

Vijay Kumar

Evercore ISI

$40

Buy

86.39%

Upside

Reiterated

01/12/26

Enovis free cash flow set to improve in FY26, says Evercore ISIEnovis free cash flow set to improve in FY26, says Evercore ISI

Danielle Antalffy

UBS

$57→$50

Buy

132.99%

Upside

Reiterated

01/05/26

Analysts' Opinions Are Mixed on These Healthcare Stocks: Zoetis (NYSE: ZTS), Enovis (NYSE: ENOV) and Icon (NASDAQ: ICLR)

Caitlin Cronin

Canaccord Genuity

$58→$50

Buy

132.99%

Upside

Reiterated

12/17/25

Enovis (ENOV) Gets a Buy from Canaccord Genuity

Keith Hinton

Freedom Capital Markets

$45

Buy

109.69%

Upside

Initiated

12/16/25

Enovis (ENOV) Initiated with a Buy at Freedom Capital Markets

Jeff Johnson

Robert W. Baird

$50→$45

Buy

109.69%

Upside

Reiterated

11/07/25

Enovis price target lowered to $45 from $50 at BairdEnovis price target lowered to $45 from $50 at Baird

Vik Chopra

Wells Fargo

$41→$42

Buy

95.71%

Upside

Reiterated

11/07/25

Michael Matson

Needham

$49

Buy

128.33%

Upside

Reiterated

11/06/25

Enovis: Strong Financial Performance and Growth Potential Justify Buy Rating

Robbie Marcus

J.P. Morgan

$33

Hold

53.77%

Upside

Reiterated

08/08/25

Analysts' Top Healthcare Picks: DENTSPLY SIRONA (XRAY), Replimune Group (REPL)

Jason Wittes

Roth MKM

$75

Buy

249.49%

Upside

Reiterated

08/08/25

Enovis (ENOV) Gets a Buy from Roth MKM

Young Li

Jefferies

$60

Buy

179.59%

Upside

Reiterated

05/30/25

Optimistic Buy Rating for Enovis: Strong Growth, Margin Expansion, and Attractive Valuation

David Turkaly

Citizens JMP

$62→$55

Buy

156.29%

Upside

Reiterated

05/09/25

Enovis price target lowered to $55 from $62 at Citizens JMPEnovis price target lowered to $55 from $62 at Citizens JMP

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Enovis

3 Months

xxx

Success Rate

5/14 ratings generated profit

Average Return

-1.26%

reiterated a xxx

rating 3 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 35.71% of your transactions generating a profit, with an average return of -1.26% per trade.

1 Year

Vijay KumarEvercore ISI

Success Rate

2/10 ratings generated profit

Average Return

-11.24%

reiterated a buy rating 18 days ago

Copying Vijay Kumar's trades and holding each position for 1 Year would result in 20.00% of your transactions generating a profit, with an average return of -11.24% per trade.

2 Years

xxx

Success Rate

0/10 ratings generated profit

Average Return

-21.35%

reiterated a xxx

rating 18 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 0.00% of your transactions generating a profit, with an average return of -21.35% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

ENOV Analyst Recommendation Trends

Rating

Sep 25

Oct 25

Nov 25

Dec 25

Jan 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, ENOV has received 14 Buy Ratings, 36 Hold Ratings, and 1 Sell Ratings. ENOV average Analyst price target in the past 3 months is 45.25.

Each month's total comprises the sum of three months' worth of ratings.

ENOV Financial Forecast

ENOV Earnings Forecast

Next quarter’s earnings estimate for ENOV is $0.83 with a range of $0.79 to $0.97. The previous quarter’s EPS was $0.75. ENOV beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.25% of the time in the same period. In the last calendar year ENOV has Performed in-line its overall industry.

ENOV Sales Forecast

Next quarter’s sales forecast for ENOV is $583.78M with a range of $572.90M to $591.00M. The previous quarter’s sales results were $548.91M. ENOV beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 49.18% of the time in the same period. In the last calendar year ENOV has Performed in-line its overall industry.

ENOV Stock Forecast FAQ

What is ENOV’s average 12-month price target, according to analysts?

Based on analyst ratings, Enovis’s 12-month average price target is 45.25.

What is ENOV’s upside potential, based on the analysts’ average price target?

Enovis has 110.86% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is ENOV a Buy, Sell or Hold?

Enovis has a consensus rating of Strong Buy which is based on 9 buy ratings, 0 hold ratings and 0 sell ratings.

What is Enovis’s price target?

The average price target for Enovis is 45.25. This is based on 9 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $50.00 ,the lowest forecast is $40.00. The average price target represents 110.86% Increase from the current price of $21.46.

What do analysts say about Enovis?

Enovis’s analyst rating consensus is a Strong Buy. This is based on the ratings of 9 Wall Streets Analysts.

How can I buy shares of ENOV?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Enovis (ENOV) Stock Forecast & Price Target

ENOV Analyst Ratings

ENOV Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Enovis

ENOV Analyst Recommendation Trends

ENOV Financial Forecast

ENOV Earnings Forecast

ENOV Sales Forecast

ENOV Stock Forecast FAQ

Detailed List of Analyst Forecasts